Q2'23 was a solid quarter, with sales of USD 210m (2% above ABGSCe,1% above company collected consensus), corresponding to a total sales growth of 11% (ABGSCe 9%, cons. 10%). The growth was driven by all segments and regions, with most notably prosthetics sales performing very well during the quarter. Prosthetics sales were up 20% y-o-y, with total sales of USD 103m, 8% above ABGSCe and 6% above cons. Additionally, the quarter saw an almost historic high percentage of prosthetics sales coming from the high-margin, high-tech sub-segment bionics, which accounted for 25% of prosthetics sales during the quarter. EBITDA came in at USD 37m, slightly below cons at USD 38m).
Aktuellt
SENASTE
